MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/acr-24-239

Медицинская библиотека · AME case reports · 2025

Efficacy and safety of dostarlimab in elderly patients with multiple comorbidities and allergic diathesis: case report.

Lanzafame Katia, Blanco Giusi, D'Asta Marco, Sapienza Mirella, Bonanno Giulia Maria, Ettore Carla, Giurato Eliana, Paratore Sabrina, Russo Angela, Vallone Antonino, Bordonaro Roberto, Ettore Giuseppe

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Several studies have demonstrated the effectiveness of anti-programmed death-1 (PD-1) drugs in patients suffering from deficient mismatch repair/microsatellite instability (dMMR/MSI) endometrial cancer (EC). The phase III Ruby study, showed benefit in progression-free survival (PFS) for patients with stage III-IV EC, both MSI-high/dMMR (MSI-H/dMMR) and mismatch repair proficient/microsatellite stable (pMMR/MSS), treated upfront with chemotherapy in combination with dostarlimab. Even earlier, the GARNET trial, which enrolled patients with advanced or relapsed EC with dMMR and/or MSI progressing on prior platinum therapy to receive dostarlimab, reported overall response rate (ORR) of 43.5% with a manageable safety profile. We report on the case of an elderly patient with many pathologies treated with dostarlimab.

CASE DESCRIPTION: A 75-year-old woman with EC (MSI-H) with pulmonary and bone metastasis progressed on first line chemotherapy platinum-containing, was treated with dostarlimab as monotherapy. Medical history was positive for arterial hypertension, autoimmune thrombocytopenia and allergy to amoxicillin and levofloxacin. After the second administration of dostarlimab, our patient showed a dramatic improvement of her clinical conditions. The clinical response was confirmed by radiological response on the basis of the results of a computed tomography (CT) scan performed in March 2023 that showed a reduction of the pelvic mass and pulmonary secondaries. No toxicities related to autoimmune thrombocytopenia occurred. The experienced grade 2 infusion reaction, resolved with the suspension of the drug and the administration of an antihistaminic drug; then we resumed dostarlimab doubling the administration time.

CONCLUSIONS

The administration of dostarlimab is safe and feasible in elderly people with multiple pathologies and multiple allergies with recurrent dMMR/MSI EC. The drug is well tolerated and able to give a good quality of life to patients.

Для цитирования: Lanzafame Katia, Blanco Giusi, D'Asta Marco, Sapienza Mirella, Bonanno Giulia Maria, Ettore Carla, Giurato Eliana, Paratore Sabrina, Russo Angela, Vallone Antonino, Bordonaro Roberto, Ettore Giuseppe. Efficacy and safety of dostarlimab in elderly patients with multiple comorbidities and allergic diathesis: case report.. AME case reports. 2025. DOI: 10.21037/acr-24-239.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.